文献速递肿瘤 PET/CT

探索肺腺癌与肺鳞癌的代谢图景:全身[18F]FDG PET/CT方法

Exploring the metabolic landscape of lung adenocarcinoma and squamous cell carcinoma: a total-body [18F]FDG PET/CT approach.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-03

本研究采用全身静态与动态[18F]FDG PET/CT及基于互信息的网络方法,回顾性分析32例早期未治疗肺癌患者(腺癌与鳞癌)和20名健康志愿者的器官间代谢依赖关系。腺癌患者表现为选择性代谢连接增强,尤其在中枢神经系统与肾上腺、胰腺等外周器官之间;鳞癌患者则表现为广泛的代谢连接降低。作者认为全身PET/CT联合网络方法可定量可视化肺癌的系统性代谢改变,但需更大规模纵向研究验证。

要点

  • 腺癌患者代谢连接选择性增强,尤其中枢神经系统与肾上腺、胰腺之间。
  • 鳞癌患者代谢连接广泛降低,提示系统性代谢 breakdown。
  • 全身PET/CT联合网络方法可定量可视化肺癌系统性代谢改变。

核心结论

  • 全身PET/CT联合基于网络的方法有助于定量可视化肺癌的系统性代谢改变。
  • 腺癌与鳞癌表现出独特的代谢谱,可能为疾病进展及治疗监测的潜在生物标志物提供线索。
  • 作者认为需要更大规模、纵向研究来验证这些发现并进一步探索其用于早期诊断和治疗分层的临床相关性。

研究设计与样本

  • 回顾性研究,纳入32例早期未治疗肺癌患者和20名健康志愿者。
  • 采用全身静态与动态PET/CT扫描评估全身葡萄糖消耗。
  • 选取代表主要器官的25个感兴趣区(ROI),以平均SUV和Ki值量化代谢状态。
  • 采用互信息(MI)量化器官间代谢依赖关系,并进行Bonferroni校正控制多重比较。
  • 构建群体水平代谢网络及每位癌症患者的个体化网络。

主要发现

  • 腺癌患者与健康对照相比,代谢连接出现选择性增强,尤其在中枢神经系统与肾上腺、胰腺等外周器官之间,提示代偿性神经内分泌机制激活。
  • 鳞癌患者与健康对照相比,代谢连接广泛降低,提示与疾病进展相关的系统性代谢 breakdown。
  • 个体水平网络分析揭示了个人化的代谢偏差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需要更大规模、纵向研究来验证这些发现并进一步探索其临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cancer is increasingly recognized not just as a localized disease but as a systemic condition with profound impacts on metabolism at both cellular and whole-body levels. This study seeks to unveil the systemic metabolic disruptions in early-stage, untreated lung cancer patients, specifically adenocarcinoma (ADC) and squamous cell carcinoma (SqCC), using a novel network-based approach with total-body static and dynamic PET/CT imaging. By analyzing inter-organ metabolic dependencies, we aim to uncover how lung cancer induces whole-body metabolic reprogramming, providing insights into potential biomarkers for monitoring disease progression and treatment response. METHODS: This retrospective study included 32 early-stage untreated lung cancer patients and 20 healthy volunteers. Static and dynamic total-body PET/CT scans were performed to assess glucose consumption across the body. Twenty-five regions of interest (ROIs) representing major organs were selected, and metabolic status was quantified using the average SUV and Ki values for each ROI. Inter-organ metabolic dependencies were quantified using mutual information (MI), which measures the amount of shared information between two variables, capturing both linear and nonlinear relationships, followed by Bonferroni correction to control for multiple comparisons. Population-level metabolic networks were constructed to visualize alterations in interregional connectivity for ADC, SqCC, and healthy cohorts. Furthermore, to capture personalized metabolic deviations, individual networks were constructed for each cancer patient. RESULTS: The analysis revealed distinct metabolic network patterns in ADC and SqCC patients compared to healthy controls. ADC patients exhibited selective enhancements in metabolic connectivity, particularly between the central nervous system and peripheral organs such as the adrenal glands and pancreas, suggesting activation of compensatory neuroendocrine mechanisms. In contrast, SqCC patients showed widespread reductions in metabolic connectivity, indicative of a systemic metabolic breakdown associated with disease progression. Individual-level network analysis highlighted personalized metabolic deviations. CONCLUSION: Total-body PET/CT combined with network-based methods facilitates the quantitative visualization of systemic metabolic alterations in lung cancer. ADC and SqCC exhibit unique metabolic profiles that may offer insights into disease progression and the identification of potential biomarkers for therapeutic monitoring. Larger, longitudinal studies are required to validate these findings and further explore their clinical relevance for early diagnosis and treatment stratification in lung cancer. CLINICAL TRIAL NUMBER: Not applicable.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Tao X, Wang H, Qu J, et al. Exploring the metabolic landscape of lung adenocarcinoma and squamous cell carcinoma: a total-body [18F]FDG PET/CT approach. Eur J Nucl Med Mol Imaging. 2025. PMID: 40457067. doi:10.1007/s00259-025-07371-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。